BioVie to present Phase 2 bezisterim Long COVID trial results at ANA 2026 meeting

• BioVie flagged new Phase 2 findings for bezisterim in Long COVID, set for poster presentation at ANA2026 on Oct. 18.
• The company also plans to present initial Phase 2 results for bezisterim in early Parkinson’s disease at the same meeting on Oct. 19.
• Both readouts focus on efficacy and safety observations, with disclosures positioned as new data updates rather than final trial outcomes.
• The presentations are scheduled for Oct. 17–20 in San Diego, giving investors a near-term catalyst across two indications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610140800PRIMZONEFULLFEED9845001) on October 14, 2026, and is solely responsible for the information contained therein.